Harvest Technologies Corp.
This article was originally published in Start Up
Harvest is building upon the autotransfusion concept to create devices which not only have the capacity to collect a patient's blood just prior to and during surgery, but which can also convert collected blood into autologous blood products that promote post-surgical wound healing, bone growth and hemostasis.
You may also be interested in...
Harvest Technologies, a 14-year-old player in the blood and marrow supply arena, is moving aggressively into the business of selling stem cells therapies for cardiovascular disease.
Lilly announced it signed strategic international agreements with four diabetes companies to advance connected solutions and streamline care for people with diabetes in markets outside of the US.